Voyager Therapeutics, Inc. (VYGR)
Pre-Market:
| Previous Close | 7.65 |
| Open | 7.65 |
| Bid | 5.50 x 200 |
| Ask | 7.61 x 100 |
| Day's Range | 7.45 - 7.66 |
| 52 Week Range | 6.06 - 14.34 |
| Volume | |
| Avg. Volume | 643,261 |
| Market Cap | 411.056M |
| Beta (5Y Monthly) | 0.95 |
| PE Ratio (TTM) | 2.55 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Voyager Therapeutics (NASDAQ:VYGR) has had a rough week with its share price down 14%. However, a closer look at its...
- Barrons.com
Buy Voyager Stock, Analyst Says. The Little Biotech Could Have Big Breakthroughs.
Voyager Therapeutics has surely tried investors’ patience since it came public eight years ago. The biotech firm’s stock has fallen as low as $2.50 from a peak of $30, as its early programs to treat neurological diseases didn’t pan out. Analysts at Guggenheim Securities initiated coverage of the Lexington, Mass.-based biotech with a Buy rating earlier this week.
- Insider Monkey
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we discuss 12 most undervalued biotech stocks to buy according to hedge funds. If you want to skip our discussion on the biotech industry, head over to 5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds. Fitch Ratings maintains a Neutral outlook for the global pharmaceutical and biotech industry in […]
